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Abstract Several studies suggested that staging bonemarrow
biopsy (BMB) could be omitted in patients with classical
Hodgkin’s lymphoma (cHL) when a positron emission
tomography/computed tomography (PET/CT) is performed
at baseline.
To address the concordance between BMB and PET/CT in
the detection of bone marrow involvement (BMI) and the
BMB role in determining the Ann Arbor stage, we retrospec-
tively collected data on 1244 consecutive patients with cHL
diagnosed from January 2007 to December 2013. One thou-
sand eighty-five patients who had undergone both BMB and
PET/CT were analyzed, comparing the Ann Arbor stage
assessed with PET/CT only to that resulting from PET/CT
combined with BMB.
One hundred sixty-nine patients (16%) showed at least one
focal skeletal lesion (FSL) at PET/CT evaluation. Only 55
patients had a positive BMB (5.1%); 34 of them presented at
least one FSL at PET/CT. To the contrary, 895 out of 1030
patients with a negative BMB did not show any FSL (86.9%).
Positive and negative predictive values of PET/CT for BMI
were 20 and 98%, respectively; sensitivity and specificity
were 62 and 87%, respectively. Fifty-four out of 55 patients
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with a positive BMB could have been evaluated as an ad-
vanced stage just after PET/CT; only one patient (0.1%)
would have been differently treated without BMB.
Our data showed a very high negative predictive value of
PET/CT for BMI and a negligible influence of BMB on treat-
ment planning, strengthening the recent indications that BMB
could be safely omitted in cHL patients staged with PET/CT.
Keywords Positron emission tomography . Computed
tomography . Hodgkin’s lymphoma . Bonemarrow biopsy .
Staging
Introduction
Classical Hodgkin lymphoma (cHL) accounts for approxi-
mately 8% of newly diagnosed lymphomas, with a rather sta-
ble incidence [1]. It is nowadays a highly curable disease, with
lasting remissions in more the 70–80% of patients after
first-line therapy [2]. Treatment strategy is based on Ann
Arbor stage and risk classification, so the pre-therapeutic
work-up is crucial to avoid over-treatment in limited-stage
patients and under-treatment of advanced-stage patients.
The Ann Arbor classification represented a cornerstone in
cHL staging [3]; in 1989, staging was reviewed in the
Cotswold meeting in order to limit invasive procedures,
thanks to the improvement of imaging diagnostics [4]. Bone
marrow involvement in cHL is not frequent, accounting for 4–
11% of new patients [5] and is usually associated with the
presence of B symptoms [6, 7]. Iliac crest bonemarrow biopsy
(BMB) is an invasive procedure for staging of patients with
newly diagnosed cHL according to the 2010 ESMO guideline
[8]. However, BMB investigates only a limited volume of
bone marrow, and so it could miss partial, localized lympho-
matous infiltration [9]. Moreover, BMB is associated with a
small risk of complications, including hemorrhages and infec-
tions in the bioptic site (in up to 0.12% of patients) [10], and it
may cause anxiety and pain to the patient [11, 12].
18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography/computed tomography (PET/CT) is today recom-
mended in the initial staging of cHL [13], response assessment
after treatment [14], and for prognostic assessment as an in-
terim scan [15]. Awhole-body, non-invasive diagnostic instru-
ment, PET/CT exhibits impressive accuracy in the identifica-
tion of nodal and extranodal disease, including skeletal lesions
[13, 16], leading frequently to an upstaging of patients when
compared to CT scan alone.
Several studies have evaluated the role of BMB in the PET/
CT era [17–27]. The largest one, by El-Galaly et al., has ret-
rospectively reported data on the diagnostic and prognostic
value of routine BMB in 454 treatment-naive patients with
cHL undergoing PET/CT staging, showing that in light of
the results of BMB, no patient was upstaged or had a change
in treatment [21]. Recently, a meta-analysis evaluated the di-
agnostic performance of PET/CT in detecting bone marrow
involvement in cHL patients, concluding that PET/CT could
appropriately substitute BMB in the staging of cHL [28].With
the aim of increasing the knowledge of this issue, we per-
formed a multi-centric, retrospective study on consecutive
cHL patients referring to hematology centers of the
Fondazione Italiana Linfomi, aimed at establishing the con-
cordance between BMB and PET/CT in the detection of bone
marrow involvement in cHL and to evaluate the impact of
BMB in the staging of patients with cHL.
Methods
Patients
Consecutive cHL patients diagnosed from January 2007
to December 2013 referring to 16 hematological centers
of the Fondazione Italiana Linfomi were included in this
retrospective study. The study was approved by the ethical
committee of the coordinating center (Florence, Italy) and
was conducted according to the Helsinki Declaration.
Informed consent was obtained from all individuals par-
ticipants included in the study. Data were collected from
electronic database and patient charts. All data were col-
lected in an anonymized format, in compliance with insti-
tutional and national requirements.
Patients more than 14 years old were included in the study
if both PET/CT and BMB had been performed at baseline.
The exclusion criteria were (i) diagnosis of nodular
lymphocyte-predominant HL, (ii) HIV positivity, (iii) other
previous or concomitant malignancy, (iv) and a follow-up of
less than 3 months after the end of therapy.
All patients were evaluated according to the Ann Arbor
staging system by the combination of both PET/CT and
BMB and by the use of PET/TC only [2]. Risk stratification
was performed according to the categories identified by the
German Hodgkin Study Group (GHSG) and, for patients in
advanced stage, to the Hasenclever score [29, 30]. Response
to treatment was defined according to the International
Working Group criteria [31].
Evaluation of BMB
BMB had been performed unilaterally or bilaterally according
to local policies and were evaluated by local pathologists
without a central review. Minimal requirements for immuno-
histochemical staining were pan-B, pan-T, CD30, and CD15.
BMB was repeated at the end of the treatment if positive at
baseline [31].
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Evaluation of PET/CT
PET/CT were performed according to local protocols and
scanner procedures. PET/CT were performed by
co-registration of PET and multislice CT in a single,
whole-body session; a low-dose CT was employed in most
cases. Scans were performed from skull base to mid-tights
and were registered 60–90 min after the intravenous injection
of 18F-FDG; different doses of 18F-FDG were administered
depending on the type of PET/CT scanner. PET/CT was re-
peated at the end of treatment [31] and, in most cases, after
two cycles of treatment with ABVD as prognostic interim
evaluation [14].
Interpretation of skeletal lesions
Due to the retrospective nature of this study, investigators
could decide to further evaluate focal skeletal lesions accord-
ing to their internal policies. In absence of a histological ver-
ification via guided biopsies or supplementary radiological
studies, focal skeletal lesions were considered as a disease
involvement if a focal 18F-FDG uptake above liver
18F-FDG uptake disappeared or persisted, according to other
involved sites, in PET/CT studies performed after chemother-
apy [32]. Focal skeletal lesions were categorized as unifocal (a
single PET-positive site), bifocal (two PET-positive sites), and
multifocal (three or more PET-positive lesions). Awidespread
marrow 18F-FDG uptake above liver 18F-FDG uptake in ab-
sence of focal skeletal lesions defined as above was not con-
sidered as a disease involvement. PET/CT scans of patients
with focal skeletal uptakes were locally reviewed by a differ-
ent nuclear medicine physician; no central review was
performed.
Statistical analysis
Measures of diagnostic performance, such as positive predic-
tive value (PPV), negative predictive value (NPV), sensitivity,
and specificity, were estimated with the corresponding confi-
dence intervals, based on the obtained results and on the num-
ber of false negatives (FN) and false positives (FP). Lastly, the
agreement in the definition of the Ann Arbor stage between
PET/CT plus BMB and PET/CT alone was assessed, evaluat-
ing also whether the omission of BMB could modify the pa-
tient management.
Results
We retrospectively collected data from 1244 patients with
cHL diagnosed in 16 hematology centers of the Fondazione
Italiana Linfomi; 159 patients were excluded because of a lack
of baseline BMB or PET/CT. Patient characteristics are
reported in Table 1. The median age of the 1085 evaluable
patients was 33 years (range 14–89 years), and 567 patients
(52.3%) were male. Only 47 patients were less than 18 years
old, with a median age of 17 years. As expected, nodular
sclerosis was the most common histological subtype (769 pa-
tients, 70.9%); 455 patients (41.9%) reported B-symptoms at
presentation. One hundred ninety-one patients (17.6%)
underwent a bilateral BMB, while in the large majority of
patients (890 patients, 82%), BMB was unilateral. A positive
BMB was reported in only 55 patients (5.1%), without differ-
ences between patients who underwent unilateral or bilateral
BMB. All analyzed patients reached the minimum required
follow-up of 3 months.
The analysis of skeletal 18F-FDG uptake is summarized in
Table 2. Overall, the PET/CT scans featured at least a focal
skeletal lesion in 169 patients (15.6%); in particular, 56 pa-
tients showed a single focal lesion, 32 had two focal lesions,
and 81 presented three or more focal lesions. Considering the
patients with a negative BMB, 48 (4.7%) showed a single
bone lesion, 30 (2.9%) had two lesions, and 57 patients
(5.5%) displayed three or more lesions. Of the 55 patients with
a positive BMB, eight (14.6%) had a unifocal skeletal
18F-FDG uptake, two (3.6%) a bifocal involvement, and 24
(43.6%) a multifocal localization. A diffuse and homogeneous
marrow 18F-FDG uptake was observed in 53 patients (5.1%)
with a negative BMB and in nine patients (16.3%) with a
positive BMB. Nonetheless, all of them have been considered
Table 1 Baseline patient characteristics
Median age (range): 33 years (14–80)
Sex (%):
Male 567 (52.34%)
Female 518 (47.7%)
Histotypes (%):
Nodular sclerosis 769 (70.9%)
Mixed cellularity 210 (19.3%)
Lymphocyte-rich 42 (3.9%)
Lymphocyte-depleted 12 (1.1%)
Not otherwise specified 52 (4.8%)
Bulky disease (%):
Yes 295 (27.2%)
No 790 (72.8%)
B-symptoms (%):
Yes 455 (41.9%)
No 622 (57.3%)
Not reported 8 (0.8%)
Bone marrow biopsy site (%):
Unilateral 890 (82%)
Bilateral 191 (17.6%)
Not reported 4 (0.4%)
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a stage IV with PET/CT only because of other extranodal
18F-FDG uptake sites (seven lung lesions, two liver lesions).
The sensitivity and specificity of focal skeletal PET/CT
lesions for detection of positive versus negative BMB were
61.8% (CI 95%, 47.7–74.6) and 86.9% (CI 95%, 84.7–88.9),
respectively. PPV and NPV of focal skeletal PET/CT lesions
for detection of positive BMB were 20.1% (CI 95%, 14.3–
27.0) and 97.7% (CI 95%, 96.5–98.6), respectively.
We also evaluated the sensitivity, NPV, and the diagnostic
accuracy of both BMB and PET/CT under the assumption that
both of them are separately sufficient to reveal true bone or
marrow disease. For BMB, the sensitivity was 28.9% (CI
95%, 26.3–31.8), NPV was 86.9% (CI 95%, 84.7–88.8), and
the diagnostic accuracy was 88% (CI 95%, 84.5–89.0%). For
PET/CT, the sensitivity was 86.5% (CI 95%, 84.3–88.5), NPV
was 97.8% (CI 95%, 96.7–98.5), and the diagnostic accuracy
was 98% (CI 95%, 96.0–98.5%).
A surgical- or CT-guided bone biopsy was performed in
only four out of 169 patients with at least a focal skeletal
lesion (2.4%); in three of them, the biopsy confirmed a disease
involvement, while one patient underwent a CT-guided needle
biopsy of a rib, which did not reveal a lymphomatous locali-
zation. This patient was considered a stage III according to the
results of PET/CT.
The results of the staging considering the PET/CT scan
alone or the PET/CT and BMB are represented in Table 3.
With the PET/CT scan alone, 55 patients (5.1%) were in stage
I, while 532 (49%), 258 (23.7%), and 240 (22.1%) resulted in
stages II, III, and IV, respectively. The addition of BMB to
PET/CT led to the upstaging of nine patients (0.8%). In par-
ticular, none of the patients in stage I with PET/CT alone was
upstaged, while one out of 532 patients in stage II (0.1%; CI
95%, <0.0001–0.0117)) and eight out of 258 in stage III
(3.1%; CI 95%, 0.0099–0.0521) with PET/CT alone were
upstaged to stage IV with the addition of BMB.
In the 1059 patients assessed according to the GHSG risk
score, none of the 184 patients in the early group and only one
out of the 291 patients in the intermediate group (3.4%; CI
95%, <0.0001–0.0212) shifted to the advanced group after the
incorporation of BMB to PET/CT.
Discussion
In the last years, new imaging techniques have become avail-
able in routine clinical practice, greatly modifying the diag-
nostic approach of many hematological diseases. PET/CT is
currently employed in the baseline assessment of cHL as well
as in the treatment response evaluation [13, 14] and for prog-
nostic assessment as an interim scan [15].
With the widespread availability of high-quality PET/CT
scanners, which co-registrate PETandmultislice CTscans in a
single whole-body examination, the possibility to detect
extranodal sites of disease has become realistic, thanks to the
high sensitivity of PET/CT in the detection of bone marrow
involvement in cHL, as reported in many series [17–21].
BMB is the classical procedure to detect bone marrow in-
volvement in lymphomas, but it is an invasive, possibly pain-
ful procedure, which samples only a limited part of bone mar-
row. In the past years, efforts were done in order to develop
scores constituted of laboratory and clinical data to evaluate
the probability of marrow involvement in cHL [5], but they
never entered the routine daily practice. Recently, considering
the very low positivity rate of BMB in patients with cHL [9]
and the astonishing results of PET/CT, the role of BMB as a
mandatory staging procedure has been debated. Several au-
thors reported their data in relatively small cohorts of patients
[21–27]; the largest population was described by El-Galaly
et al. [21] who reported data on 454 newly diagnosed patients
with cHL. With a negative predictive value of focal skeletal
lesions of 99% and no patient upstaged with the addition of
BMB, the authors considered that omission of BMB would
have not affected the treatment choice [21]. This issue was
further evaluated in a meta-analysis of nine studies performed
by Adams et al., which included 955 patients from 9 different
studies. Pooled sensitivity and specificity of PET/CT ranged
Table 2 Correlation between
skeletal lesions identified by
PET/CT and bone marrow biopsy
results
Patients with negative BMB (N = 1030) Patients with positive BMB (N = 55)
N % N %
Skeletal lesions at PET/CT
Unifocal 48 4.7 8 14.6
Bifocal 30 2.9 2 3.6
Multifocal 57 5.5 24 43.6
No focal lesions 895 86.9 21 38.2
Diffuse homogeneous skeletal 18F–FDG uptake
53 5.1 9 16.4
BMB bone marrow biopsy, PET positron emission tomography, CT computed tomography. 18F-FDG 18F-
fluorodeoxyglucose
1150 Ann Hematol (2017) 96:1147–1153
Author's personal copy
were 96.9 and 99.7%, respectively, and even with considering
the moderate quality of the studies included, the evidence was
that PET/CT may replace BMB in the staging of cHL [28].
We present in this paper the results of a large retrospective,
multi-center study including consecutive cHL patients refer-
ring to centers of the Fondazione Italiana Linfomi. To our
knowledge, this represents the largest cohort of consecutive
patients analyzed with the aim to address these issues. In our
large population, a histological confirmation of disease in-
volvement trough BMB was observed in 55 out of 1085 pa-
tients (5.1%), while 169 patients (15.5%) featured at least one
focal skeletal lesion at PET/CT.
A diffuse, homogeneous marrow 18F-FDG uptake was
observed in 62 out of 1085 patients (5.7%), a similar propor-
tion when compared to other populations [21]. Nine of these
62 patients had a positive BMB, a different finding compared
to El-Galaly’s data, which otherwise showed an absence of
BMB positivity in patients with a diffuse marrow 18F-FDG
uptake. However, these nine patients could already be consid-
ered as stage IV after PET/CT alone because of other
extranodal 18-F FDG uptake sites at PET/CT.
The sensitivity and specificity of focal skeletal lesions at
PET/CT for identification of positive versus negative BMB
were 61.8 and 86.9%, respectively. Most importantly, despite
the low PPVof focal skeletal lesions (20.1%), we found a very
high NPV (97.7%), confirming that the absence of focal skel-
etal lesions at PET/CT could be roughly associated to a neg-
ative BMB. These results are even more meaningful consid-
ering that a thorough bioptic evaluation of extranodal and
skeletal sites of 18F-FDG uptake is unfeasible, either for tech-
nical and ethical reasons and to avoid a treatment delay. The
lower sensitivity showed in our study compared to El-Galaly’s
data [21] could possibly be explained with the different refer-
ence level used to determine the disease involvement of bone
lesions, which were considered positive if showed a focal
18F-FDG uptake above liver 18F-FDG uptake, while in the
El-Galaly’s study, the mediastinal blood pool was used as
reference. We chose a more selective reference in order to
minimize the number of false positives; considering the lower
sensitivity, the NPV was particularly high, and we could then
consider the liver reference as a suitable reference to evaluate
bone lesions.
A striking finding in our study, however, is than even if the
addition of BMB to PET/CT led to an upstage in nine patients,
only one patient (0.1%) had a change in the risk group allo-
cation and treatment choice, while the remaining eight patients
could have been already considered as an advanced stage with
PET/CT only.
Undoubtedly, the major limits of our study are represented
by the lack of a central review of the PET/CT scans and the
absence of a standardization method for the evaluation of
PET/CT scans, which were performed according to local pro-
cedures. Despite their importance, these limitations give a
Breal-life^ perspective to our results and could be applied to
the majority of patients treated outside a clinical trial.
Notwithstanding a partial level of evidence, recent recom-
mendations indicate that a BMB is no longer required for the
routine evaluation of patients with cHL undergoing a PET/CT
at baseline [33], as well as the latest ESMO guidelines, which
suggested with a grade IIIB level of evidence that BMB could
be omitted if patients are staged with PET/CT [34].
Our data strengthen the aforementioned evidence on safely
omitting BMB as a staging procedure in the initial assessment
of cHL patients when undergoing a PET/CT scan. However,
BMB could provide information not only about disease in-
volvement but also on marrow cellularity and the presence
of dysplastic features; these data could help the treating phy-
sicians to evaluate the hematopoietic reserve in a more accu-
rate fashion, which may be useful in elderly patients and in
those patients who present with cytopenias or abnormalities of
blood smear. Although BMB does not add information about
the actual stage, we therefore suggest evaluating clinical and
Table 3 PET/CT versus PET/CT
and bone marrow biopsy staging
and risk assessment
According to
PET/CT
According to
PET/CT and BMB
PET/CT vsPET/CT and BMB
Ann Arbor stage
I 55 55 No difference
II 532 531 −1 (0.0019 CI 95%: <0.0001–0.0117)
III 258 250 −8 (0.031 CI 95% 0.0099–0.0521)
IV 240 249 +9 (0.037 CI 95% 0.0135–0.0615)
GHSG risk score
Not reported 26 26 No difference
Early 184 184 No difference
Intermediate 291 290 −1 (0.0034 CI 95%: <0.0001–0.0212)
Advanced 584 585 + 1 (0.017 CI 95% <0.0001–0.0051)
PET positron emission tomography, CT computed tomography, BMB bone marrow biopsy, GHSG German
Hodgkin Study Group
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laboratory data for single patients before definitely discarding
BMB (or a marrow aspiration, which could also give informa-
tion about hematopoietic lineages) from the diagnostic
work-up.
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